Providing review services for clinical trials involving infectious diseases.
Official title: Single Institutional Review Board (sIRB)
Funded at Advarra, INC. · NIH-11202821 · Data updated 2026-11-12
This study is all about making sure that people taking part in clinical trials for infectious diseases, like those caused by Treponema pallidum, are treated fairly and safely, so that we can find better treatments for these conditions.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Advarra, INC. NIH-funded |
| Lab location | 1 site (Columbia, United States) |
| Project start | April 1, 2024 |
| Project end | March 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $221,281 |
| NIH project number | 75N93024D00002-0-759302400002-2 |
| Project ID | NIH-11202821 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation are individuals involved in or affected by clinical trials related to infectious diseases.
✕Less likely to help
Patients not involved in clinical trials or those with non-infectious diseases may not receive direct benefits from this research.
What this research studies
This research focuses on offering Institutional Review Board (IRB) services for specific studies conducted by the National Institute of Allergy and Infectious Diseases (NIAID) at various sites across the United States. The IRB will ensure that the rights and welfare of participants in clinical trials are protected, particularly in studies related to infectious diseases such as those caused by Treponema pallidum. Patients may benefit from the oversight and ethical review of clinical trials that aim to improve treatments for communicable diseases.
Why it matters
Potential benefit: If successful, this research could enhance the safety and ethical standards of clinical trials for infectious diseases, leading to better patient outcomes.
How similar studies have gone: Other research has shown that effective IRB oversight significantly improves the ethical conduct of clinical trials, indicating a successful precedent for this approach.
Where this research is happening
-
Advarra, INC.
Columbia, United States Active
Researchers
- Principal investigator: Atkinson, Rebecca — Advarra, INC.
- Study coordinator: Atkinson, Rebecca
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.